Dr. Theresa Deisher’s career has focused on discovering and developing new therapies
for grievous human illness. Dr. Deisher obtained her PhD in Molecular and Cellular
Physiology from Stanford University and has spent over 19 years in commercial
biotechnology, working with such illustrious companies as Genentech, Repligen,
ZymoGenetics, Immunex and Amgen, prior to founding AVM Biotechnology and
Sound Choice Pharmaceutical Institute. AVM Biotechnology is the marquee prolife
biotech company worldwide, certifying that it does not use morally illicit material in
any process.
Dr. Deisher is an inventor on 23 issued US patents, and her discoveries have led to
clinical trials of FGF18 for osteoarthritis and cartilage repair, and for Factor XIII for
surgical bleeding. Dr. Deisher was the first person to discover adult cardiac derived
stem cells, and has been a champion of adult stem cell research, both professionally and
privately, for two decades. Dr. Deisher is a plaintiff in the US federal lawsuit to
prohibit use of federal tax payer dollars for embryo destructive research. She is a frequent lecturer on the stem cell
issues delving into topics such as ; research, clinical progress, policy, economics and ethics.
5:45
36:19
3:44
